11.04.24 -- How To Promote Batch-To-Batch Consistency In CAR-T Therapies

Review the importance of alternative approaches to viral vector production and the benefits of intensified adherent cell culture for improving efficiency, reducing costs, and accelerating development.

Because clinical applications for AAV are increasing rapidly, there is a high demand for further increasing yields as well as product quality, particularly for a higher percentage of full capsids in the final product.

Learn how the streamlined processes and reduced complexity enabled by a platform approach can lead to scalable manufacturing, rapid delivery, and expanded patient access for cell therapies.

See how a next-generation rAAV production platform delivers high yields and superior product quality across various serotypes and genome lengths through innovative process optimization.

Implementing NGS technology for adventitious virus testing in viral vector vaccine development and manufacturing is crucial for ensuring safety. Gain insights for an optimized sequencing method.

Advance sustainable oligonucleotide manufacturing by adopting innovative solutions that reduce environmental impact while addressing the growing demand for therapeutic oligonucleotides.

In this presentation, speakers share how the University of Queensland rapidly developed a vaccine candidate for COVID-19 and the role GS Xceed system played in the project.

Explore the development work involved for the individual technologies that make up an innovative and scalable, chemical-free continuous viral vector production platform.

NK cells represent a promising avenue for immunotherapy. Examine the advantages of NK cells in cellular immunotherapy and the importance of developing efficient activation and expansion platforms.

A CRISPR research institute needed a custom, ultra-pure nuclease with low endotoxins—see how Aldevron's expertise lowered immune responses compared to AAV serotype 9.